BTS India Private Equity Fund Limited has revealed that it will invest around $7 million in Parabolic Drugs. The latter is an emerging pharmaceutical company in Chandigarh.

The capital will be used for funding Parabolic's next level of growth and will be largely used for significantly expanding capacities for its existing and new products.

With this, the Fund managed by Swiss based BTS Group has completed yet another investment in pharmaceutical sector which is one of its preferred sectors. Several of the pharmaceutical companies invested through its earlier Fund have been doing exceedingly well and some of these have been nominated by CNBC TV18, ICICI Bank and CRISIL for the SME awards.

Parabolic Drugs, which has facilites at Derabbasi and Panchkula near Chandigarh, has already established itself with several global pharmaceutical companies as an important supplier for APIs and bulk drugs ranging across several products in the betalactum and cephalosporins range.

"The current round of capital raising is a step towards further broadening the product and customer base, and take the company towards its target of crossing Rs. 10 billion in sales over the next couple of years," said Pranav Gupta, Chairman and Managing Director of Parabolic.

The company has obtained type II USFDA approval and Certificate of Suitability for some of its products. It is currently in the process of filing several DMFs and CEPs for further strengthening its exposure to the regulated markets both in Europe and US.

Going forward, it also plans to enter non beta lactum products in the next two to three years. The company has set up a dedicated research and development centre in line with its plan for future growth.